Alnylam Pharmaceuticals, Inc. (ALNY) Competitors & Peers
The 5 largest companies in the same industry as Alnylam Pharmaceuticals, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $548.22 | P/E 35.3RSI 57Cap 139.1 B |
| REGN | Partner | $910.29 | P/E 20.1RSI 63Cap 94.3 B |
| ARGX | Peer | $963.70 | P/E 33.4RSI 62Cap 60.7 B |
| RVMD | Peer | $190.50 | RSI 53Cap 40.5 B |
| CSLLY | Peer | $34.25 | P/E 18.2RSI 71Cap 66.6 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- REGNPartner
Regeneron and Alnylam are partnered on discovering and developing RNAi therapeutics for eye and central nervous system diseases.
Model-inferred, unverified — treat as a lead, not evidence - NVSPartner
Alnylam-Novartis Leqvio (inclisiran) for hypercholesterolemia.
Model-inferred, unverified — treat as a lead, not evidence - BBIOCompetitor
BridgeBio's acoramidis competes with Alnylam's RNAi drugs for amyloidosis treatment.
Model-inferred, unverified — treat as a lead, not evidence